Background: Multiple sclerosis (MS) is a common neurologic autoimmune disorder. We have used a newly introduced measure, Quality of Care Index (QCI), which is associated with the efficacy of care given to patients suffering from MS. Objectives: The aims of the study were to report and compare the quality of care given to MS patients in different regions and country. Methods: Primary measures were retrieved from Global Burden of Disease (GBD) from 1990 to 2019. Secondary measures (mortality-to-incidence ratio, DALY-to-prevalence ratio, prevalence-to-incidence ratio, and YLL-to-YLD ratio) were combined using principal component analysis, to form an essential component (QCI) (0–100 index with higher values representing better condition). Results: In 2019, there were 59,345 (95% UI: 51,818–66,943) new MS incident cases globally. Global QCI of 88.4 was calculated for 2019. At national level, Qatar had the highest quality of care (100) followed by Kuwait (98.5) and Greenland (98.1). The lowest QCI was observed in Kiribati (13.5), Nauru (31.5), and Seychelles (36.3), respectively. Most countries have reached gender equity during the 30 years. Also, QCI was lowest in ages from 55 to 80 in global scale. Conclusion: MS QCI is better among those countries of higher socioeconomic status, possibly due to better healthcare access and early detection in these regions. Countries could benefit from adopting the introduced QCI to evaluate the quality of care given to MS patients at national and global level.

Reich DS, Lucchinetti CF, Calabresi PA. Multiple sclerosis. N Engl J Med. 2018;378(2):169–80.
Compston A, Coles A. Multiple sclerosis. Lancet. 2008;372(9648):1502–17.
GBD 2016 Multiple Sclerosis Collaborators. Global, regional, and national burden of multiple sclerosis 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2019;18(3):269–85.
GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990–2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–22.
Pekic S, Stojanovic M, Popovic V. Controversies in the risk of neoplasia in GH deficiency. Best Pract Res Clin Endocrinol Metab. 2017;31(1):35–47.
Mohammadi E, Ghasemi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, Ebrahimi Meimand S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of brain and other central nervous system cancers; global burden of disease systematic analysis 1990-2017. PLoS One. 2021;16(2):e0247120.
Mohammadi E, Ghasemi E, Saeedi Moghaddam S, Yoosefi M, Ghanbari A, Ahmadi N, et al. Quality of care index (QCI).; 2020. Available from:
Moore KA, Vandivere S, Redd Z. A sociodemographic risk index. Soc Indic Res. 2006;75(1):45–81.
Zhao YB, Gan XQ, Luo P, He Q, Guo QD, Zhang L, et al. The risk of osteopenia in premenopausal women with various sellar tumors. Gynecol Endocrinol. 2012;28(12):945–8.
Furgal-Borzych A, Lis GJ, Litwin JA, Rzepecka-Wozniak E, Trela F, Cichocki T. Increased incidence of pituitary microadenomas in suicide victims. Neuropsychobiology. 2007;55(3–4):163–6.
Świątkowska-Stodulska R, Babińska A, Mital A, Stodulski D, Sworczak K. Hemostatic disorders in hormonally active pituitary tumors. Exp Clin Endocrinol Diabetes. 2015;123(9):548–52.
GBD 2019 Universal Health Coverage Collaborators. Measuring universal health coverage based on an index of effective coverage of health services in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020;396(10258):1250–84.
Westlund K. Distribution and mortality time trend of multiple sclerosis and some other diseases in Norway. Acta Neurol Scand. 1970;46(4):455–83.
Sahraian MA, Sahebkar M, Dehghani R, Derakhshan-Jazari M, Kazami-Moghaddam V, Kouchaki E. Multiple sclerosis-a disease on a dramatically rising trend in iran: review of possible reasons. Iran J Neurol. 2017;16(1):34–40.
Noonan CW, Kathman SJ, White MC. Prevalence estimates for MS in the United States and evidence of an increasing trend for women. Neurology. 2002;58(1):136–8.
Cutter GR, Koch MW. Multiple sclerosis diagnostic criteria. Moving ahead or walking in place?Neurology. 2022;98(1):12–3.
Liu Z, Liao Q, Wen H, Zhang Y. Disease modifying therapies in relapsing-remitting multiple sclerosis: a systematic review and network meta-analysis. Autoimmun Rev. 2021;20(6):102826.
Azadnajafabad S, Saeedi Moghaddam S, Mohammadi E, Rezaei N, Ghasemi E, Fattahi N, et al. Global, regional, and national burden and quality of care index (QCI) of thyroid cancer: a systematic analysis of the Global Burden of Disease Study 1990-2017. Cancer Med. 2021;10(7):2496–508.
Adelman G, Rane SG, Villa KF. The cost burden of multiple sclerosis in the United States: a systematic review of the literature. J Med Econ. 2013;16(5):639–47.
Asche CV, Singer ME, Jhaveri M, Chung H, Miller A. All-cause health care utilization and costs associated with newly diagnosed multiple sclerosis in the United States. J Manag Care Pharm. 2010;16(9):703–12.
Prescott JD, Factor S, Pill M, Levi GW. Descriptive analysis of the direct medical costs of multiple sclerosis in 2004 using administrative claims in a large nationwide database. J Manag Care Pharm. 2007;13(1):44–52.
Petruzzo M, Palladino R, Nardone A, Nozzolillo A, Servillo G, Orlando V, et al. The impact of diagnostic criteria and treatments on the 20-year costs for treating relapsing-remitting multiple sclerosis. Mult Scler Relat Disord. 2020;38:101514.
Aljumah M, Alroughani R, Alsharoqi I, Bohlega SA, Dahdaleh M, Deleu D, et al. Future of management of multiple sclerosis in the middle East: a consensus view from specialists in ten countries. Mult Scler Int. 2013;2013:952321.
Deleu D, Mir D, Al Tabouki A, Mesraoua R, Mesraoua B, Akhtar N, et al. Prevalence, demographics and clinical characteristics of multiple sclerosis in Qatar. Mult Scler. 2013;19(6):816–9.
Kurtzke JF. Geographic distribution of multiple sclerosis: an update with special reference to Europe and the Mediterranean region. Acta Neurol Scand. 1980;62(2):65–80.
Eskandarieh S, Heydarpour P, Minagar A, Pourmand S, Sahraian MA. Multiple sclerosis epidemiology in east Asia, south east Asia and south Asia: a systematic review. Neuroepidemiology. 2016;46(3):209–21.
Chong HT. Multiple sclerosis in south east Asia and diagnostic criteria for asians. Neurol Asia. 2008;13(2):145–6.
Aminorroaya A, Yoosefi M, Rezaei N, Shabani M, Mohammadi E, Fattahi N, et al. Global, regional, and national quality of care of ischaemic heart disease from 1990 to 2017: a systematic analysis for the Global Burden of Disease Study. European Journal of Preventive Cardiology; 2017. p. 2021.
Keykhaei M, Masinaei M, Mohammadi E, Azadnajafabad S, Rezaei N, Saeedi Moghaddam S, et al. A global, regional, and national survey on burden and Quality of Care Index (QCI) of hematologic malignancies; global burden of disease systematic analysis 1990–2017. Exp Hematol Oncol. 2021;10(1):11–5.
You do not currently have access to this content.